<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8D6A87B-48C3-49DC-8D55-AA7203607683"><gtr:id>A8D6A87B-48C3-49DC-8D55-AA7203607683</gtr:id><gtr:name>University of British Columbia (UBC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:postCode>B-9000</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/05411D8E-491B-4AF2-A38D-04082B8FA53E"><gtr:id>05411D8E-491B-4AF2-A38D-04082B8FA53E</gtr:id><gtr:name>Samsung Advanced Institute of Technology</gtr:name><gtr:address><gtr:line1>Sait</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8D6A87B-48C3-49DC-8D55-AA7203607683"><gtr:id>A8D6A87B-48C3-49DC-8D55-AA7203607683</gtr:id><gtr:name>University of British Columbia (UBC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:postCode>B-9000</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/05411D8E-491B-4AF2-A38D-04082B8FA53E"><gtr:id>05411D8E-491B-4AF2-A38D-04082B8FA53E</gtr:id><gtr:name>Samsung Advanced Institute of Technology</gtr:name><gtr:address><gtr:line1>Sait</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/365AE3B7-F093-48B1-83B3-35E085126B4A"><gtr:id>365AE3B7-F093-48B1-83B3-35E085126B4A</gtr:id><gtr:firstName>George</gtr:firstName><gtr:otherNames>Scott</gtr:otherNames><gtr:surname>Baillie</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ007412%2F1"><gtr:id>056C405B-C26C-4127-9EF0-EEED0070E887</gtr:id><gtr:title>cAMP phosphodiesterase-4: signalling complexes, regulation and potential therapeutic targets.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J007412/1</gtr:grantReference><gtr:abstractText>The death rate from respiratory diseases in the UK is twice the EU average and costs the NHS more than any other disease area. Chronic Obstructive Pulmonary Disease, the fourth leading cause of death in the world, causes around 26,000 deaths/year and asthma around 1500 deaths/yr in the UK. This debilitating illness is associated with lung damage caused by chronic inflammation due to the sustained activation of 'inflammatory' cells. Raising the levels of a substance called cAMP, inside these cells, can stop this. An effective way of doing this is to stop cAMP from being broken down by PDE4 enzymes. At the moment scientists have made inhibitor molecules that bind tightly to the 'mouth' on PDE4 where cAMP is digested, stopping it breaking down cAMP. However, a major problem using these as medicines are side-effects like nausea and vomiting. 
It's now clear that there is a large family of PDE4 enzymes where only certain of these are found in cells causing inflammation and damage in lungs. We aim to identify the particular PDE4 enzymes that it is important to inhibit in order to stop damage and help repair lungs. Then we need to devise ways to inhibit these selectively, rather than all PDE4s, to produce medicines without side-effects. As all PDE4 enzymes have identical mouths for digesting cAMP we need to take a new approach to inhibit just the critical PDE4s. To do this we will exploit our discovery that individual PDE4s have unique 'postcodes' built into them. These post-codes allow particular PDE4s to be targeted to the right place inside cells for them to work properly. This happens because the individual postcode is recognised by distinct anchor proteins placed at strategically important sites in cells. This targeting to exactly the right place is essential for particular PDE4s to do their job. We aim to identify anchor proteins and relevant postcodes for the PDE4s that we need to inhibit to stop inflammation and lung damage. Then, when we've done this, we will design molecules that stop the postcode of critical PDE4s from being recognised by their anchors. These molecules will prevent PDE4s from going to the place in the cell where they help inflammation to occur. These should provide a new way of making medicines to treat COPD that we anticipate will not suffer side effects caused by medicines currently being developed.</gtr:abstractText><gtr:technicalSummary>cAMP is a pivotal second messenger able to exert a panoply of cell type specific effects. A multigene family of phosphodiesterases (PDEs) provide the sole means for degrading cAMP and are thus poised to play a key regulatory role in cells. Highly specialised regulatory properties, coupled with cell specific patterns of expression, provide each cell type with a sophisticated and unique means of regulating intracellular cAMP. This diversity offers potential for developing highly specific therapeutic agents. There is great interest in developing PDE4 family selective inhibitors for treatment of Chronic Obstructive Pulmonary Disease (COPD). However, the deployment of PDE4 inhibitors as therapeutics has been limited by side effects, such as nausea. It is now appreciated that PDE4 activity is attributable to a large family of isoforms. This has prompted the notion that selective inhibition of particular PDE4 isoforms may maximise therapeutic benefit whilst minimising side effects. Different cell types have unique complements of PDE4 isoforms and recent technological advances place us now at a stage where we can determine how individual PDE4 isoforms sculpt cAMP gradients in cells to underpin compartmentalised cAMP signalling and control specific cellular processes. Inherent in this is the concept pioneered by our laboratory that the intracellular targeting of individual types of PDE4 isoforms to specific signalling complexes is fundamental to their functioning. Thus, not only may altered expression, targeting and regulation of individual isoforms contribute to various pathological conditions but disrupting the intracellular targeting of specific PDE4 isoforms in cells may provide a novel means of generating therapeutics aimed at disease-related PDE4 isoforms while minimising side-effects. As a route to identifying novel therapeutic targets we propose to define the functional role, modes of intracellular targeting and and regulation of PDE4 isoforms associated with COPD.</gtr:technicalSummary><gtr:potentialImpactText>Asthma causes around 74,000 emergency hospital admissions and 1500 deaths in the UK each year. However, Chronic Obstructive Pulmonary Disease has now overtaken asthma as a drain on healthcare resources. It is the fourth leading cause of death in the world, with numbers predicted to increase. In the UK, COPD causes around 30,000 deaths/year and is projected to become the third most common cause of death by 2020. It causes 300,000 emergency hospital admissions every year, representing &amp;gt;10% of all acute admissions. It currently costs the NHS &amp;pound;500 million in direct costs and almost &amp;pound;1 billion a year with indirect costs included. COPD causes working difficulties, with loss of &amp;gt;20 million working days/yr in the UK. Whilst there have been improvements in the management of this difficult disease, there is a pressing need for novel therapies to combat it, particularly as no existing treatment appears to reduce disease progression. 
While the PDE4 selective inhibitor, Roflumilast has recently been approved for use in Europe and the USA, its path to approval has been problematic, reflecting difficulties due to side effects that limit the therapeutic window. Nevertheless, the proven anti-inflammatory action of PDE4 inhibitors demonstrates the functional importance of PDE4 isoforms. The side-effect issue probably relates to the fact that 4 PDE4 genes encode &amp;gt;20 isoforms with similar catalytic units such that active-site directed inhibitors, like Roflumilast, inhibit all PDE4 species to a greater or lesser extent, rather than preferentially targeting those associated with efficacy in ameliorating COPD. Different cell types have unique complements of PDE4 isoforms and recent technological advances place us now at a stage where we can determine how individual PDE4 isoforms sculpt cAMP gradients in cells to underpin compartmentalised cAMP signalling and control specific cellular processes. Inherent in this is the concept pioneered by our laboratory that the intracellular targetinof individual types of PDE4 isoforms to specific signalling complexes is fundamental to their functioning. Thus, not only may altered expression, targeting &amp;amp; regulation of individual isoforms contribute to various pathological conditions, but disrupting the intracellular targeting of specific PDE4 isoforms in cells may provide a novel means of generating therapeutics aimed at disease-related PDE4 isoforms while minimising side-effects. We are thus uniquely placed to build on and exploit our expertise in order to translate this into identifying novel therapeutic targets and approaches.
The general public will benefit. Collaborations such as the one proposed with the Akassoglou lab, are pivotal in future research development. They increase the UK knowledge base and therefore scientific output, student teaching and postdoctoral training, which are are substantial contributors to national wealth. In addition, such collaborations reduce costs through efficient sharing of intellectual and technical resources. 
All materials generated as part of this proposal will be made freely available to other members of the scientific community.
Clinicians and patients will benefit indirectly from this work because the more we understand about the mechanisms underlying COPD, the nearer we become to an effective treatment.
Additionally, the researchers employed on this grant will acquire experience investigations into complex signalling modules and pathways and the multifaceted dynamic processes they involve. With this novel combination of competences the researchers will become competitive in the biomedical research field with an original profile. By working under the supervision of top scientists in their field and with authors of numerous highly quoted publications, they will learn how to conceive solid research projects and how to present scientific results in a clear and convincing form, with the perspective of publishing their work in high ranking peer-reviewed journals.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>492909</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Francisco</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).</gtr:description><gtr:id>3EA890FC-3A1B-47A6-AEA4-6933860A1F8F</gtr:id><gtr:impact>research papers</gtr:impact><gtr:outcomeId>545b2ca72e0587.19906502-1</gtr:outcomeId><gtr:partnerContribution>Expertise in Chemical informatics</gtr:partnerContribution><gtr:piContribution>Expertise in PDE4</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Samsung Advanced Institute of Technology</gtr:collaboratingOrganisation><gtr:country>Korea, Republic of</gtr:country><gtr:description>Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis.</gtr:description><gtr:id>D4E5F3ED-BC04-40FE-A6B8-6AF46A5BF1B4</gtr:id><gtr:impact>Research publication</gtr:impact><gtr:outcomeId>545b27379573a6.54023538-1</gtr:outcomeId><gtr:partnerContribution>Human disease model</gtr:partnerContribution><gtr:piContribution>Expertise in PDE4 and cAMP</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biomedical Sciences</gtr:department><gtr:description>Missense mutation in DISC1 C-terminal coiled-coil has GSK3beta signaling and sex-dependent behavioral effects in mice</gtr:description><gtr:id>12C26182-CDE4-4B85-8409-D237BB987FBB</gtr:id><gtr:impact>publication</gtr:impact><gtr:outcomeId>56cf1b81e160e3.51342871-1</gtr:outcomeId><gtr:partnerContribution>Animal model of behaviour</gtr:partnerContribution><gtr:piContribution>PDE4 biology research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ghent</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Phosphodiesterase 4 interacts with the 5-HT4(b) receptor to regulate cAMP signaling.</gtr:description><gtr:id>0721C25E-A01E-42A0-ADCC-3D5EB57CB2DF</gtr:id><gtr:impact>Scientific publication

Multi-disciplinary. Bochemistry, cell biology, molecular biology, pharmacology</gtr:impact><gtr:outcomeId>545b2616c3ab75.00467448-1</gtr:outcomeId><gtr:partnerContribution>Expertise on 5-HT4(b) receptor signalling</gtr:partnerContribution><gtr:piContribution>Expertise on PDE4.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Human Genetics Unit</gtr:department><gtr:description>Epidermal Growth Factor Receptor substrate 8 (Eps8) controls Src/FAK-dependent phenotypes in squamous carcinoma cells.</gtr:description><gtr:id>205A9B71-9DAF-46C2-89DF-0D49FBAAAC4A</gtr:id><gtr:impact>Research papers</gtr:impact><gtr:outcomeId>545b2a70921337.08735086-1</gtr:outcomeId><gtr:partnerContribution>Cell models, expertise in cancer research</gtr:partnerContribution><gtr:piContribution>Expertise in peptide array</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Inserm/UPS UMR 1048 Institute of Metabolic and Cardiovascular Diseases (I2MC)</gtr:department><gtr:description>Specific interactions between Epac1, beta-arrestin2 and PDE4D5 regulate beta-adrenergic receptor subtype differential effects on cardiac hypertrophic signaling</gtr:description><gtr:id>B23B7317-0763-45FA-97E9-F727CBC46F4E</gtr:id><gtr:impact>research paper</gtr:impact><gtr:outcomeId>545b2b67beabe8.99883374-1</gtr:outcomeId><gtr:partnerContribution>Cell models of cardiac disease</gtr:partnerContribution><gtr:piContribution>expertise in PDE4 and peptide array</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of British Columbia</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Department of Psychiatry</gtr:department><gtr:description>pecific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition</gtr:description><gtr:id>B4F00813-9388-4BA0-8214-B1A8605C171D</gtr:id><gtr:impact>publication</gtr:impact><gtr:outcomeId>56cf1aae4d31f2.16067702-1</gtr:outcomeId><gtr:partnerContribution>Work on mouse model of Schizophrenia</gtr:partnerContribution><gtr:piContribution>Work on PDE4 biochemistry for a paper</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of St Andrews</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Real-time probing of beta-amyloid self-assembly and inhibition using fluorescence self-quenching between neighbouring dyes</gtr:description><gtr:id>176D80E6-8DE2-4DF1-88FF-A9DA30735E0C</gtr:id><gtr:impact>2 scientific publications</gtr:impact><gtr:outcomeId>545b28dd6d38f8.81164556-1</gtr:outcomeId><gtr:partnerContribution>Biophysical assay expertise</gtr:partnerContribution><gtr:piContribution>Expertise on HSP20 and PDE4</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Expert talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6E96F7E8-5EC2-4A9B-B2A1-61B92A6610DD</gtr:id><gtr:impact>Invited speaker at the DZHK (German Centre for CardioVascular Research) workshop on &amp;quot;Cardiac second messenger microdomains&amp;quot;, University Medical Center Gottingen, Germany (Sept 2013).

Open question/answer session and 2 hour meeting giving careers advice to PhD students from all over Germany</gtr:impact><gtr:outcomeId>NRUaciRLddD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hosted 6th year school student for advanced honours project</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1F4D4CCF-176B-4F8A-8074-3ECB677E0587</gtr:id><gtr:impact>Student applied for University place in Biological Sciences

Student achieved place at Strathclyde University</gtr:impact><gtr:outcomeId>545b34dd10b855.51679330</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Technology talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AEFAE5B5-F086-4D0C-A598-1F9E8C51B2AC</gtr:id><gtr:impact>)Opening Keynote talk and conference chair at the 2nd UK xCELLigence users meeting, Birmingham (june 2013)

Introduction of academics to new technology</gtr:impact><gtr:outcomeId>W9o4na3Y2D4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media coverage of scientific paper</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>901E6967-9026-4266-BF5F-B7988D7E1F5A</gtr:id><gtr:impact>article in Scotsman and Scottish Daily Mail and Times</gtr:impact><gtr:outcomeId>56cf20994c16a0.13287096</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gordon Research seminar</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>263C4AE9-93A6-4CF4-B811-3714517D3CBB</gtr:id><gtr:impact>The purpose was to allow junior scientists to run their own conference. Thi was successful as the student sparked lively discussions aboout the future of our field

The focus of this meeting is to highlight new and innovative techniques and models that are advancing our understanding of PDEs and cyclic nucleotide signaling. These include, but are not limited to: novel biosensors, molecular modeling tools and unique in vivo and in vitro models that aid in investigating PDEs and their signaling partners. The meeting will also feature a mentorship session which will explore the challenges and changing landscape of research today, and the opportunities that exist to bridge academic and industry research.</gtr:impact><gtr:outcomeId>545b3369a779c4.84634267</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.grc.org/programs.aspx?year=2014&amp;program=grs_cycnuc</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference organisation (Peptide Array 2013) in conjunction with European Peptide Society</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FD176D33-7CC7-45CA-A452-6F1D7741C829</gtr:id><gtr:impact>Conference sparked discussion on future of peptide research

General interest in peptide array technique massively increased</gtr:impact><gtr:outcomeId>545b374853f7d7.18918484</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.eurpepsoc.com/ai1ec_event/peptide-arrays-2013/?instance_id=</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Images of Science (Glasgow Science Centre)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E38CED7E-A244-4B9F-B749-48E0B68AC490</gtr:id><gtr:impact>Contact with public has attracted several questions

Increasing public awareness of research into heart disease</gtr:impact><gtr:outcomeId>545b35f4916443.15848569</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4441D43F-3A34-4589-BAE2-220C6E1C4611</gtr:id><gtr:impact>Plenary opening talk of Annual meeting of Italian Society of Dermatology, Surgical, Esthetical and Sexually Transmitted diseases in Rome (Nov 2012, 1000 participants)

Open question and answer session</gtr:impact><gtr:outcomeId>jcqfAPcEYEC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited seminar at Gordon Research Conference on Cyclic nucleotides</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>91DD2A5E-15BE-4A0B-9EA3-E75B74083ADD</gtr:id><gtr:impact>informed PDE4 field of my latest advanced which raised many questions

Invited to be vice chair of next GRC on cyclic nucleotides inm 2016</gtr:impact><gtr:outcomeId>545b31d501d0b0.72591208</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.grc.org/programs.aspx?year=2014&amp;program=cycnuc</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Work experience for school children</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6A396488-1A6F-45F3-BC2F-395A157A7262</gtr:id><gtr:impact>The school children involved are now seriously considering careers in Biological Sciences

School children more interested in science and more likely to go for University Qualification in Sciences</gtr:impact><gtr:outcomeId>545b34429e9c97.86241331</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Glengarnock 2013)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B5FF5758-94B4-48E0-8431-2624F046C515</gtr:id><gtr:impact>30 pupils attended career talk which lead to discussion and open questions

I have had quesations re career advice from the school and pupils</gtr:impact><gtr:outcomeId>JjVeMGZ4YeV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CBA996A4-BCFA-4301-9D25-8730250DFF42</gtr:id><gtr:impact>Radio interview on Radio Clyde about the paper on&amp;quot;Adipocyte-specific p75 neurotrophin receptor regulates energy balance in obesity&amp;quot;</gtr:impact><gtr:outcomeId>56cf203a3ad502.38706635</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial placement PhD Scheme</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>33B019C6-BA20-48A4-B8B0-468FC3D5DC59</gtr:id><gtr:outcomeId>545b2f0d07da50.30691509</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Small molecules targeting the PDE4A4-p75NTR interaction, a novel target for fibrotic diseases.</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C3BF5CE9-DD01-44B3-B801-39E39ECF605D</gtr:id><gtr:outcomeId>56cf1cb9076f16.29017457</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>583000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:fundingRef>PS7305CA23</gtr:fundingRef><gtr:id>B4A08281-E375-4E5E-9BEB-E6B47B204E6C</gtr:id><gtr:outcomeId>LXtLRDRgDeR</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>73600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome PhD studentship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>096978/Z/11/Z</gtr:fundingRef><gtr:id>2334EE7D-7BBB-426C-BB28-5B7590DAA3A2</gtr:id><gtr:outcomeId>545b2fc35dd409.40558044</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>142585</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translational Award</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Heart Research UK</gtr:fundingOrg><gtr:fundingRef>RG2610/12/14</gtr:fundingRef><gtr:id>800891FE-5C27-4106-B9BE-662F007F4BBD</gtr:id><gtr:outcomeId>HXehEASJAbp</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF PhD Studentship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>96EA8680-20E4-4313-83EE-2A0F5323E4D2</gtr:id><gtr:outcomeId>545b2d82a732e8.96484042</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Disruptor peptide that increases HSP20 phosphorylation</gtr:description><gtr:grantRef>MR/J007412/1</gtr:grantRef><gtr:id>CB30AC59-4308-4E18-B34F-A19B39C12A5E</gtr:id><gtr:impact>Proof of Concept award from Scottish Enterprise</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>WjDDK9LiDg1</gtr:outcomeId><gtr:patentId>WO2012046008</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Increasing HSP20 activation in biological systems involves antagonists capable of inhibiting PDE4 binding.</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Ubiquitin E3 ligase inhibitor</gtr:description><gtr:grantRef>MR/J007412/1</gtr:grantRef><gtr:id>98F39D11-3205-4695-A7DA-04C3A0B6CA15</gtr:id><gtr:impact>Spinout company formed around the discovery</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>o36idYAEJPb</gtr:outcomeId><gtr:patentId>WO2013001297</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>New substituted peptide compounds are beta transducin repeat-containing protein modulators, useful for treating e.g. breast cancer, arthritis, osteoarthritis, rheumatoid arthritis, Crohn's disease and irritable bowel syndrome.</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>High affinity peptides designed to disrupt specified protein-protein interactions</gtr:description><gtr:id>399AA42A-1B89-4F0B-86A5-97D08A9384D6</gtr:id><gtr:impact>Scientific publications (over 20) from my group and others.</gtr:impact><gtr:outcomeId>mK6bUVr7uA5</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Disruptor peptides</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/23495691</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Antibodies against splice variants of PDE4</gtr:description><gtr:id>D300FBB9-BB69-4855-9746-90B0770A0F70</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>545b4ed62aac76.98913742</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PDE4 isoform specific antibodies</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Sannox Therapeutics</gtr:companyName><gtr:description>Biotech company</gtr:description><gtr:id>7F70DB08-3DA4-40D9-A76C-E7469F3DA33D</gtr:id><gtr:impact>Compounds under development for cardiovascular disease and cancer</gtr:impact><gtr:outcomeId>m38V3sWYA8p</gtr:outcomeId><gtr:url>https://www.companiesintheuk.co.uk/ltd/sannox-therapeutics</gtr:url><gtr:yearCompanyFormed>2013</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>5DD2B3AA-A1B4-4744-A565-69F98B222D84</gtr:id><gtr:title>Missense mutation in DISC1 C-terminal coiled-coil has GSK3? signaling and sex-dependent behavioral effects in mice.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8129f0b766d127dec41ec57700bc646"><gtr:id>a8129f0b766d127dec41ec57700bc646</gtr:id><gtr:otherNames>Dachtler J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56cf17bc143141.18705280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DFD9CBE-CBC4-4B80-8E51-D3C78324258A</gtr:id><gtr:title>Cytodynamics and endpoint selection for a reliable in vitro assessment of nanoneurotoxicity.</gtr:title><gtr:parentPublicationTitle>Nanomedicine : nanotechnology, biology, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8579e92c08f1323460247aca9cded79"><gtr:id>c8579e92c08f1323460247aca9cded79</gtr:id><gtr:otherNames>Zarros A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-9634</gtr:issn><gtr:outcomeId>56cf18095c5800.28212821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F8240A6-0554-484F-B951-AA9047257F80</gtr:id><gtr:title>Mitotic activation of the DISC1-inducible cyclic AMP phosphodiesterase-4D9 (PDE4D9), through multi-site phosphorylation, influences cell cycle progression.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/939640a883f89cedac4149739100baf3"><gtr:id>939640a883f89cedac4149739100baf3</gtr:id><gtr:otherNames>Sheppard CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>545395b7267449.18926485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>216600F8-2EFF-4B60-9516-4D08ECD7F0E6</gtr:id><gtr:title>p75 Neurotrophin Receptor Regulates Energy Balance in Obesity.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bc0f04f96a32f94af6b9e2eb3a012f9"><gtr:id>9bc0f04f96a32f94af6b9e2eb3a012f9</gtr:id><gtr:otherNames>Baeza-Raja B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>56cf17bbdfc8f1.91560796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B1D0B3B-FAD7-42E6-96F1-3A743A88AEE2</gtr:id><gtr:title>SUMOylation of DISC1: a potential role in neural progenitor proliferation in the developing cortex.</gtr:title><gtr:parentPublicationTitle>Molecular neuropsychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9312d781b5d41ba95413d123e2dade60"><gtr:id>9312d781b5d41ba95413d123e2dade60</gtr:id><gtr:otherNames>Tankou S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2296-9179</gtr:issn><gtr:outcomeId>58bff078a05ea4.49170003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28F86F11-555A-4BE1-962F-FB40A168FEB8</gtr:id><gtr:title>RACK1 to the future--a historical perspective.</gtr:title><gtr:parentPublicationTitle>Cell communication and signaling : CCS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9c7eea09a90056f1737c028a67ff659"><gtr:id>c9c7eea09a90056f1737c028a67ff659</gtr:id><gtr:otherNames>Ron D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1478-811X</gtr:issn><gtr:outcomeId>doi_23806_811X_11_53</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE866624-4C1E-4D0A-A6A6-CCB212E95528</gtr:id><gtr:title>Phosphorylation of ezrin on Thr567 is required for the synergistic activation of cell spreading by EPAC1 and protein kinase A in HEK293T cells.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/088abfdc74276a19abef11f37e045fe6"><gtr:id>088abfdc74276a19abef11f37e045fe6</gtr:id><gtr:otherNames>Parnell E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>56cf17bc9a38f9.89056372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>154A9D5B-C94B-4CA3-913F-678454759669</gtr:id><gtr:title>Exposure of mHIPPOE-14 cells to oligomycin as a tool for in vitro approaches to brain ischaemia-related pro- and epiphenomena: Time-dependent cellular response profiling</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8579e92c08f1323460247aca9cded79"><gtr:id>c8579e92c08f1323460247aca9cded79</gtr:id><gtr:otherNames>Zarros A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56cf1808be76b5.89904261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB7E76DF-062D-4CD7-A1AD-5F990C19389D</gtr:id><gtr:title>Non-genetic therapeutic approaches to Canavan disease.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19d1b74d417b3b343922a86de331d0e5"><gtr:id>19d1b74d417b3b343922a86de331d0e5</gtr:id><gtr:otherNames>Roscoe RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>58bff078664408.98689718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CA14AD1-5D60-4D97-866E-A34675576667</gtr:id><gtr:title>OS 15-08 Ang(1-7) INFLUENCES ET-1 SIGNALING THROUGH MAS</gtr:title><gtr:parentPublicationTitle>Journal of Hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b039e78c1293c4fc217761e35622fd9"><gtr:id>5b039e78c1293c4fc217761e35622fd9</gtr:id><gtr:otherNames>Hood K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0263-6352</gtr:issn><gtr:outcomeId>58bff077df9971.06555951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE59B889-812E-44D5-BA39-06F712665E5E</gtr:id><gtr:title>Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ee7ae20b4732cb4cac04ba7b51078dc"><gtr:id>3ee7ae20b4732cb4cac04ba7b51078dc</gtr:id><gtr:otherNames>Rutherford C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>585d47aedf67c8.39277139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1668D1B-6757-4CBB-9A68-29FAA442731A</gtr:id><gtr:title>Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aad052ec78f936293fddb51160ecfed0"><gtr:id>aad052ec78f936293fddb51160ecfed0</gtr:id><gtr:otherNames>Bolger GB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>pm_55f94539453d1cc3d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CDCF1EE-7F82-4BC3-A826-CB7E17743107</gtr:id><gtr:title>Phosphodiesterase 4 interacts with the 5-HT4(b) receptor to regulate cAMP signaling.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81bcf1d6a94d1ff7f60348d250ac0035"><gtr:id>81bcf1d6a94d1ff7f60348d250ac0035</gtr:id><gtr:otherNames>Weninger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>545395f7b003c8.48760794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>098B7F7B-F281-409B-9677-088C80C38595</gtr:id><gtr:title>Small heat shock protein 20 (Hsp20) facilitates nuclear import of protein kinase D 1 (PKD1) during cardiac hypertrophy.</gtr:title><gtr:parentPublicationTitle>Cell communication and signaling : CCS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3671a59fe7ec7112c44b200ff68dea5"><gtr:id>e3671a59fe7ec7112c44b200ff68dea5</gtr:id><gtr:otherNames>Sin YY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1478-811X</gtr:issn><gtr:outcomeId>56cf180a67cdb3.04910643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76C2CF33-05FF-4006-890E-8E8B776EE289</gtr:id><gtr:title>RACK1 stabilises the activity of PP2A to regulate the transformed phenotype in mammary epithelial cells.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9af707ee93434e7d3fdb37c307ac6c22"><gtr:id>9af707ee93434e7d3fdb37c307ac6c22</gtr:id><gtr:otherNames>Kiely M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>58bff078d0fa14.29572224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B3201EE-3C40-4102-8483-059D32426C0A</gtr:id><gtr:title>Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) interacts with Regulator of Chromosome Condensation (RCC1) dynamically throughout the cell cycle.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17788216f238a51cdd5ee271b7995218"><gtr:id>17788216f238a51cdd5ee271b7995218</gtr:id><gtr:otherNames>Deschamps T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>58bff077b1ee50.01605088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9910764-3E6B-4A04-A85C-CF10F4AC1157</gtr:id><gtr:title>Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e97d2ee215aebc3a5195e09cf65db848"><gtr:id>e97d2ee215aebc3a5195e09cf65db848</gtr:id><gtr:otherNames>Havekes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>585d6e274a6b09.66082221</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B81F6A4-3617-4A53-853C-6F493BADCD4D</gtr:id><gtr:title>Identification of a multifunctional docking site on the catalytic unit of phosphodiesterase-4 (PDE4) that is utilised by multiple interaction partners.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/267b5bd7a6322d2b67019428c20e740a"><gtr:id>267b5bd7a6322d2b67019428c20e740a</gtr:id><gtr:otherNames>Houslay KF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>588b63789a1f38.97162073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1744A07-9BA8-4955-8CAC-51311629D291</gtr:id><gtr:title>Heat shock protein 20 (HSP20) is a novel substrate for protein kinase D1 (PKD1).</gtr:title><gtr:parentPublicationTitle>Cell biochemistry and function</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3671a59fe7ec7112c44b200ff68dea5"><gtr:id>e3671a59fe7ec7112c44b200ff68dea5</gtr:id><gtr:otherNames>Sin YY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0263-6484</gtr:issn><gtr:outcomeId>56cf17bc4a4d40.26662523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9139F742-2127-4CE2-8E35-5C3A1DF188B6</gtr:id><gtr:title>Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1-42-mediated cytotoxicity.</gtr:title><gtr:parentPublicationTitle>FEBS open bio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e794e036cbf6d3575c456067407f520"><gtr:id>7e794e036cbf6d3575c456067407f520</gtr:id><gtr:otherNames>Cameron RT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2211-5463</gtr:issn><gtr:outcomeId>58bff0777ccf05.23383451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB1D59AD-9B67-4FE9-900D-9911BB99291C</gtr:id><gtr:title>PKA phosphorylation of p62/SQSTM1 regulates PB1 domain interaction partner binding.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/640697cd7d418484c285b7ec0d4219e8"><gtr:id>640697cd7d418484c285b7ec0d4219e8</gtr:id><gtr:otherNames>Christian F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>5453928519bf71.56644626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F88FCB2-79F9-4099-9D5B-43E9BEB296E4</gtr:id><gtr:title>Sleep deprivation causes memory deficits by negatively impacting neuronal connectivity in hippocampal area CA1.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e97d2ee215aebc3a5195e09cf65db848"><gtr:id>e97d2ee215aebc3a5195e09cf65db848</gtr:id><gtr:otherNames>Havekes R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>585d6e2c357a32.63834421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FBE0216-456F-40B9-9022-7EDC8655B17E</gtr:id><gtr:title>Angiotensin-(1-7) and angiotensin-(1-9) inhibit vascular smooth muscle cell growth and migration in vitro and vascular remodelling in vivo</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a0495167cb84b7457ecd45349fa26a0"><gtr:id>1a0495167cb84b7457ecd45349fa26a0</gtr:id><gtr:otherNames>McKinney C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56cf17bc726f38.09362227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD53032D-37D7-4657-A82F-48F7E170DD58</gtr:id><gtr:title>UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4fb28c7b7f759ed5da54d4f587d639a"><gtr:id>c4fb28c7b7f759ed5da54d4f587d639a</gtr:id><gtr:otherNames>Wang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>doi_55f98698639465a3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E2C063F-03A8-40AF-A9F7-6DD835BDD530</gtr:id><gtr:title>Compartmentalisation of second messenger signalling pathways.</gtr:title><gtr:parentPublicationTitle>Current opinion in genetics &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cef2879f006c2f8bd2497b3cb503319d"><gtr:id>cef2879f006c2f8bd2497b3cb503319d</gtr:id><gtr:otherNames>McCormick K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-437X</gtr:issn><gtr:outcomeId>545394fb092af6.58667022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>878B1788-B1FF-4BF8-9E05-7DE01D76E269</gtr:id><gtr:title>PTEN controls glandular morphogenesis through a juxtamembrane ?-Arrestin1/ARHGAP21 scaffolding complex.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5bc56ff125ae0a906d92553ffdf2d71"><gtr:id>a5bc56ff125ae0a906d92553ffdf2d71</gtr:id><gtr:otherNames>Javadi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5a35ce9068a8b9.83885250</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3038D674-6760-4258-A895-D186E555B4D1</gtr:id><gtr:title>Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e794e036cbf6d3575c456067407f520"><gtr:id>7e794e036cbf6d3575c456067407f520</gtr:id><gtr:otherNames>Cameron RT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>doi_23806_013_02_026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D6101B2-71CD-4E14-A1D8-2AE3A58F9D76</gtr:id><gtr:title>Acetylcholinesterase activity as a neurotoxicity marker within the context of experimentally-simulated hyperprolinaemia: An in vitro approach.</gtr:title><gtr:parentPublicationTitle>Journal of natural science, biology, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d99b66e85a8793771c9ba42c1dd6fc6f"><gtr:id>d99b66e85a8793771c9ba42c1dd6fc6f</gtr:id><gtr:otherNames>Kalafatakis K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0976-9668</gtr:issn><gtr:outcomeId>56cf1809e1ca43.12884002</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C44DC390-00EB-4B09-BCB7-8887514E30D0</gtr:id><gtr:title>The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d05a60e5a2e40af13296a88e5a2d67d8"><gtr:id>d05a60e5a2e40af13296a88e5a2d67d8</gtr:id><gtr:otherNames>Byrne AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>56cf1809b68991.63532472</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5875F9A-D24B-427B-95F1-5DFA0FDBA0DB</gtr:id><gtr:title>Location, location, location: PDE4D5 function is directed by its unique N-terminal region.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5053385f33cb00b557c941eb5f455c3f"><gtr:id>5053385f33cb00b557c941eb5f455c3f</gtr:id><gtr:otherNames>Wills L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>58bff0783a9884.73310435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C0BEA17-F311-494A-811F-652F077F9AC4</gtr:id><gtr:title>Gpr161 anchoring of PKA consolidates GPCR and cAMP signaling.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60cc5680c667c3f1d2ffe28fa22afe96"><gtr:id>60cc5680c667c3f1d2ffe28fa22afe96</gtr:id><gtr:otherNames>Bachmann VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58bff07810c901.37322380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55926CF6-6EDA-446D-AF64-D1242DE10F1A</gtr:id><gtr:title>FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2539792114260323926f19e6c60a0202"><gtr:id>2539792114260323926f19e6c60a0202</gtr:id><gtr:otherNames>Yalla K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>5a661771cf5fa0.15285384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>213D5622-93BF-4DFF-9E69-A4F5216C79AF</gtr:id><gtr:title>Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7209f07090c31c51c0fde45f6d88a3c5"><gtr:id>7209f07090c31c51c0fde45f6d88a3c5</gtr:id><gtr:otherNames>B?ttcher R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>56cf1809873999.95303327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>761E75CE-48C4-4D99-A38F-D76BB60F218E</gtr:id><gtr:title>Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17cfc5bbc1667a3216a65a4886363bcc"><gtr:id>17cfc5bbc1667a3216a65a4886363bcc</gtr:id><gtr:otherNames>McGirr A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>56cf180a146974.21295442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F685F77-732D-4CB8-A621-D1D0072D3122</gtr:id><gtr:title>Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc7177c267be2c7f56f6dd8591136b00"><gtr:id>fc7177c267be2c7f56f6dd8591136b00</gtr:id><gtr:otherNames>Zoccarato A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>56cf180a8cedd7.27463330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A95A485-0816-4B36-B70B-78B6715C8DC9</gtr:id><gtr:title>Interaction between integrin a5 and PDE4D regulates endothelial inflammatory signalling.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f42419bd6507e48cd8ce21209dddb312"><gtr:id>f42419bd6507e48cd8ce21209dddb312</gtr:id><gtr:otherNames>Yun S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>585d6e2459fc14.95664630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F872537A-C796-46AE-A031-92F64878C710</gtr:id><gtr:title>The role and therapeutic targeting of a-, ?- and ?-secretase in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Future science OA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c99933a30a66e83214ad6f277624ea0c"><gtr:id>c99933a30a66e83214ad6f277624ea0c</gtr:id><gtr:otherNames>MacLeod R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2056-5623</gtr:issn><gtr:outcomeId>58bff07908d600.73166592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FB7B079-9CB2-43D5-A0A7-2AF56CC09E0A</gtr:id><gtr:title>Arrestin regulation of small GTPases.</gtr:title><gtr:parentPublicationTitle>Handbook of experimental pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e794e036cbf6d3575c456067407f520"><gtr:id>7e794e036cbf6d3575c456067407f520</gtr:id><gtr:otherNames>Cameron RT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0171-2004</gtr:issn><gtr:outcomeId>5453934b897862.44761934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF47077B-1731-4190-AF31-2E69B9B662B4</gtr:id><gtr:title>Targeted disruption of the heat shock protein 20-phosphodiesterase 4D (PDE4D) interaction protects against pathological cardiac remodelling in a mouse model of hypertrophy.</gtr:title><gtr:parentPublicationTitle>FEBS open bio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/485fd267fefa682a0d793791a80149d2"><gtr:id>485fd267fefa682a0d793791a80149d2</gtr:id><gtr:otherNames>Martin TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2211-5463</gtr:issn><gtr:outcomeId>doi_55f9459453da0a3c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECEB35F9-7C81-404E-93FA-8EE1F6B09489</gtr:id><gtr:title>Cyclic AMP-specific phosphodiesterase, PDE8A1, is activated by protein kinase A-mediated phosphorylation.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1bc22221e02b007ecc36e2cf2f985a7d"><gtr:id>1bc22221e02b007ecc36e2cf2f985a7d</gtr:id><gtr:otherNames>Brown KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>doi_23806_012_04_033</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J007412/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>